Wenbin Li
Beijing Titan Hospital,Capital Medical University · Beijing Tiantan Hospital · Beijing Tiantan Hospital of Capital Medical University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Wenbin Li as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:41 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07138001 · Phase 2 Clinical Trial of KH617Sichuan Honghe Biotechnology Co., Ltd. · not yet recruiting · Recurrent Glioblastoma · principal investigator
- Ph1NCT06902350 · Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid TumorsChipscreen Biosciences, Ltd. · recruiting · Neoplasms, Glioblastoma, Adult, Small Cell Lung Carcinoma (SCLC) · principal investigator
- Ph2NCT06598787 · A Study of BL-B01D1 in Patients With Recurrent GlioblastomaSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Recurrent Glioblastoma · principal investigator
- Ph2/Ph3NCT06105619 · A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).Beijing Pearl Biotechnology Limited Liability Company · active not recruiting · Glioblastoma · principal investigator
- Ph3NCT05913037 · FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform NeurofibromasShanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · active not recruiting · Neurofibromatosis 1, Plexiform Neurofibroma, NF1 · principal investigator
- Ph1NCT05892653 · A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain TumorsABM Therapeutics Shanghai Company Limited · terminated · Primary Malignant Brain Tumor · principal investigator
- Ph1NCT05667194 · Phase 1 Trial of KH617Sichuan Honghe Biotechnology Co., Ltd. · recruiting · Advanced Solid Tumors · principal investigator
- Ph1/Ph2NCT05485753 · A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)Sichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma · principal investigator
- Ph2NCT05447195 · Phase 2 Study of CAN008 in Subjects With GBMCANbridge Life Sciences Ltd. · unknown · Newly-diagnosed Glioblastoma · principal investigator
- Ph1NCT04794972 · A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid TumorsSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Recurrent Glioma, Solid Tumor · principal investigator
- Ph1NCT04178057 · Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.Genor Biopharma Co., Ltd. · unknown · Brain Tumor · principal investigator
- Ph2/Ph3NCT03758014 · Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM PatientsSichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd · unknown · GBM · study director
- Ph1NCT02978261 · Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade GliomasBeijing Pearl Biotechnology Limited Liability Company · completed · Glioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 8 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 10:41 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Phase I clinical trial of a novel procaspase-3 activator SM-1 with temozolomide in recurrent high-grade gliomas.Neoplasia · 20252 citationsRCR 0.4
- SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High-Grade Gliomas: A Multicenter, Open-Label Phase I Study.Ann Clin Transl Neurol · 20252 citationsRCR 0.3